IntegriChain, Inc., a commercial insight provider supporting the pharmaceutical industry, announces the launch of its new DNA: Dynamic NextGen Analytics™ (DNA) platform. This powerful new analytic platform helps pharmaceutical manufacturers unlock the value of Direct Data through data integration, enrichment and guided analytics. Direct Data includes those data assets typically provided to the manufacturer as a function of other agreements such as fee for service, rebates, coupon programs and chargebacks.
"The pharmaceutical industry is swamped with data, both syndicated and direct. Yet answers to fundamental questions are still difficult to find. Newly emerging data sets including syndicated retail data are compounding the problem," states Kevin Leininger, IntegriChain's CEO. "Poor data quality, high cost, high latency and the historical ad-hoc nature of projects in our industry have created pressure for pharmaceutical executives. Pre-existing solutions have simply been inadequate to allow manufacturers to build a sufficient value proposition around what should be a widely leveraged, shared data asset."
IntegriChain's DNA platform has been built upon a SaaS architecture and scales to support dynamic analysis of a billion+ transaction volumes with minimal latency. The robust architecture, data warehousing and analytic capabilities of DNA can be accessed via a zero-footprint web interface, further reducing the total cost of ownership for IntegriChain's customers.
As part of the DNA: NextGen Analytics platform, IntegriChain is providing customers with a series of advanced analytical modules — DNA: Channel™, DNA: Chargeback Validation ® and DNA: Measurement of Retail Inventory™ — to maximize the value of Direct Data within multiple functions of the commercial pharmaceutical organization, including Trade Operations, Finance, Managed Markets and Brand Marketing. Through DNA: Channel, IntegriChain now offers the opportunity for customers to directly connect with trading partners, providing near real-time, on-line access to all EDI data streams. All of the analytics within the platform leverage IntegriChain's Enriched Channel Sales™, the company's unparalleled channel data enrichment service that brings full transparency and strong business value to traditionally redacted and, therefore, unusable channel data. The DNA platform will allow IntegriChain to rapidly deploy additional analytic modules as the pharmaceutical industry continues to evolve.
"DNA is a low latency platform that uses a customer's own data to quickly and inexpensively answer a whole host of questions critical to the new commercial model emerging in pharma. DNA solves manufacturers' inherent data challenges," noted Leininger.
DNA: Dynamic NextGen Analytics from IntegriChain is available now and is currently in production at IntegriChain's industry-leading clients, spanning small, medium and top-tier pharmaceutical manufacturers. IntegriChain offers a rapid deployment program that can have most manufacturers fully implemented in less than 90 days.
IntegriChain embraces the concept of guided analytics — a combination of cutting-edge business intelligence technology, advanced visualization, statistical tools and subject matter expertise. DNA: Dynamic NextGen Analytics is the only single source solution for collection, enrichment, query and advanced analytics of all Direct Data, providing 100 percent visibility to commercial demand in a low-latency business insight platform.
DNA repair process key to memory formation, study finds